Amicus Therapeutics, Inc. (FOLD)
USD 7.5
(-6.31%)
USD 7.5
(-6.31%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 198.06 Million USD | -34.7% |
| 2022 | 303.3 Million USD | 55.6% |
| 2021 | 194.93 Million USD | -30.0% |
| 2020 | 278.49 Million USD | 313.26% |
| 2019 | 67.38 Million USD | -72.15% |
| 2018 | 241.99 Million USD | 109.67% |
| 2017 | 115.41 Million USD | 454.44% |
| 2016 | -32.56 Million USD | -16.78% |
| 2015 | -27.88 Million USD | -186.75% |
| 2014 | -9.72 Million USD | 66.66% |
| 2013 | -29.16 Million USD | 12.34% |
| 2012 | -33.27 Million USD | -35.13% |
| 2011 | -24.62 Million USD | 9.59% |
| 2010 | -27.23 Million USD | -76.43% |
| 2009 | -15.43 Million USD | 42.57% |
| 2008 | -26.87 Million USD | 35.18% |
| 2007 | -41.46 Million USD | -384.26% |
| 2006 | -8.56 Million USD | -57.54% |
| 2005 | -5.43 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 234.72 Million USD | -0.0% |
| 2024 Q1 | 234.73 Million USD | 18.51% |
| 2023 Q4 | 198.06 Million USD | 3.72% |
| 2023 Q2 | 240.85 Million USD | -17.35% |
| 2023 Q1 | 291.41 Million USD | -3.92% |
| 2023 FY | 198.06 Million USD | -34.7% |
| 2023 Q3 | 190.97 Million USD | -20.71% |
| 2022 Q1 | 214.38 Million USD | 9.98% |
| 2022 Q2 | 215.4 Million USD | 0.47% |
| 2022 Q3 | 173.27 Million USD | -19.56% |
| 2022 Q4 | 303.3 Million USD | 75.04% |
| 2022 FY | 303.3 Million USD | 55.6% |
| 2021 FY | 194.93 Million USD | -30.0% |
| 2021 Q2 | 265.2 Million USD | 3.53% |
| 2021 Q3 | 53.48 Million USD | -79.83% |
| 2021 Q1 | 256.15 Million USD | -8.02% |
| 2021 Q4 | 194.93 Million USD | 264.45% |
| 2020 Q3 | 229.94 Million USD | 510.82% |
| 2020 Q1 | 86.53 Million USD | 28.41% |
| 2020 Q2 | 37.64 Million USD | -56.49% |
| 2020 FY | 278.49 Million USD | 313.26% |
| 2020 Q4 | 278.49 Million USD | 21.11% |
| 2019 Q4 | 67.38 Million USD | 72.87% |
| 2019 FY | 67.38 Million USD | -72.15% |
| 2019 Q1 | 111.09 Million USD | -54.09% |
| 2019 Q2 | -32.57 Million USD | -129.32% |
| 2019 Q3 | 38.98 Million USD | 219.66% |
| 2018 Q1 | 52.44 Million USD | -54.56% |
| 2018 Q3 | 116.98 Million USD | 21.69% |
| 2018 Q4 | 241.99 Million USD | 106.86% |
| 2018 FY | 241.99 Million USD | 109.67% |
| 2018 Q2 | 96.12 Million USD | 83.29% |
| 2017 Q2 | 121.77 Million USD | 8.63% |
| 2017 FY | 115.41 Million USD | 454.44% |
| 2017 Q4 | 115.41 Million USD | 18.37% |
| 2017 Q3 | 97.5 Million USD | -19.93% |
| 2017 Q1 | 112.1 Million USD | 447.3% |
| 2016 Q1 | 14.99 Million USD | 153.79% |
| 2016 FY | -32.56 Million USD | -16.78% |
| 2016 Q4 | -32.27 Million USD | -198.09% |
| 2016 Q3 | 32.9 Million USD | 1909.1% |
| 2016 Q2 | 1.63 Million USD | -89.08% |
| 2015 Q3 | 30.56 Million USD | 112.27% |
| 2015 FY | -27.88 Million USD | -186.75% |
| 2015 Q1 | -14.43 Million USD | -48.4% |
| 2015 Q2 | -249.02 Million USD | -1625.73% |
| 2015 Q4 | -27.88 Million USD | -191.24% |
| 2014 Q1 | -13.11 Million USD | 55.02% |
| 2014 FY | -9.72 Million USD | 66.66% |
| 2014 Q2 | -27.54 Million USD | -109.99% |
| 2014 Q3 | -5.36 Million USD | 80.51% |
| 2014 Q4 | -9.72 Million USD | -81.11% |
| 2013 Q4 | -29.16 Million USD | 1.63% |
| 2013 Q2 | -22.97 Million USD | 12.09% |
| 2013 Q1 | -26.13 Million USD | 21.44% |
| 2013 FY | -29.16 Million USD | 12.34% |
| 2013 Q3 | -29.64 Million USD | -29.03% |
| 2012 Q4 | -33.27 Million USD | -42.36% |
| 2012 Q3 | -23.37 Million USD | 15.14% |
| 2012 Q1 | -22.79 Million USD | 7.42% |
| 2012 FY | -33.27 Million USD | -35.13% |
| 2012 Q2 | -27.54 Million USD | -20.82% |
| 2011 Q4 | -24.62 Million USD | -14.78% |
| 2011 Q1 | -25.67 Million USD | 5.72% |
| 2011 FY | -24.62 Million USD | 9.59% |
| 2011 Q3 | -21.45 Million USD | 11.05% |
| 2011 Q2 | -24.11 Million USD | 6.08% |
| 2010 Q3 | -19.4 Million USD | 10.0% |
| 2010 FY | -27.23 Million USD | -76.43% |
| 2010 Q4 | -27.23 Million USD | -40.38% |
| 2010 Q2 | -21.55 Million USD | 28.32% |
| 2010 Q1 | -30.07 Million USD | -94.82% |
| 2009 Q3 | -16.24 Million USD | -24.91% |
| 2009 Q2 | -13 Million USD | 41.74% |
| 2009 Q4 | -15.43 Million USD | 4.98% |
| 2009 FY | -15.43 Million USD | 42.57% |
| 2009 Q1 | -22.32 Million USD | 16.95% |
| 2008 Q3 | -18.28 Million USD | -76.43% |
| 2008 Q1 | -15.86 Million USD | 61.74% |
| 2008 FY | -26.87 Million USD | 35.18% |
| 2008 Q4 | -26.87 Million USD | -47.02% |
| 2008 Q2 | -10.36 Million USD | 34.69% |
| 2007 Q3 | -16.83 Million USD | 26.9% |
| 2007 Q1 | -16.6 Million USD | -93.9% |
| 2007 Q2 | -23.03 Million USD | -38.74% |
| 2007 Q4 | -41.46 Million USD | -146.26% |
| 2007 FY | -41.46 Million USD | -384.26% |
| 2006 Q4 | -8.56 Million USD | 0.0% |
| 2006 FY | -8.56 Million USD | -57.54% |
| 2005 Q4 | -5.43 Million USD | 0.0% |
| 2005 FY | -5.43 Million USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 454.067% |
| Alkermes plc | -166.73 Million USD | 218.787% |
| Agenus Inc. | 274.13 Million USD | 27.749% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 89.408% |
| Aptorum Group Limited | 1.35 Million USD | -14495.305% |
| Ardelyx, Inc. | 34.51 Million USD | -473.902% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -4527.687% |
| Bicycle Therapeutics plc | -481.46 Million USD | 141.138% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -447.701% |
| ChromaDex Corporation | -24.04 Million USD | 923.624% |
| Chimerix, Inc. | -25.51 Million USD | 876.208% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -2742.463% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 936.529% |
| CRISPR Therapeutics AG | -150.84 Million USD | 231.304% |
| Precision BioSciences, Inc. | -85.41 Million USD | 331.899% |
| Dyadic International, Inc. | -6.37 Million USD | 3205.392% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 1343.112% |
| Fortress Biotech, Inc. | 7.66 Million USD | -2484.018% |
| Lantern Pharma Inc. | -21.7 Million USD | 1012.604% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 279.184% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 2418.4% |
| Incyte Corporation | -3.17 Billion USD | 106.238% |
| IO Biotech, Inc. | -140.69 Million USD | 240.772% |
| Jaguar Health, Inc. | 29.39 Million USD | -573.897% |
| Novavax, Inc. | -298.29 Million USD | 166.399% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -3611.167% |
| Opthea Limited | 28.15 Million USD | -603.42% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 1279.731% |
| ContextLogic Inc. | -232 Million USD | 185.373% |
| MiMedx Group, Inc. | -33.9 Million USD | 684.245% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -1842.766% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 8648.239% |
| NextCure, Inc. | -6.47 Million USD | 3157.974% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 492.2% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 3204.954% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -1528.387% |
| Vaxcyte, Inc. | -368.22 Million USD | 153.789% |
| PDS Biotechnology Corporation | -32.7 Million USD | 705.539% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -1046.342% |
| Pharming Group N.V. | 109.8 Million USD | -80.38% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 1238.566% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 213.031% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 1169.474% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 1169.474% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 2889.648% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 3479.949% |
| Acelyrin, Inc. | -216.9 Million USD | 191.315% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 3630.402% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 11588.689% |
| Summit Therapeutics Inc. | 34.67 Million USD | -471.221% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 3011.436% |
| Senti Biosciences, Inc. | 1.74 Million USD | -11283.046% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 207.29% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 355.729% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 3367.321% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -198423.589% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -31439.013% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 269.22% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 217.733% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | -78.646% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 2707.491% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 253.403% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -2772.756% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 181.722% |
| Immix Biopharma, Inc. | -17.5 Million USD | 1231.167% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 162.54% |
| MEI Pharma, Inc. | -3.7 Million USD | 5445.884% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -1483.127% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | -22.457% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -612.643% |
| Fortress Biotech, Inc. | 7.66 Million USD | -2484.018% |
| Precigen, Inc. | -481 Thousand USD | 41277.755% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -1306.612% |
| AlloVir, Inc. | -62.69 Million USD | 415.933% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 456.142% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -221.19% |
| ImmuCell Corporation | 10.99 Million USD | -1702.137% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 228.492% |
| Onconetix, Inc. | 5.33 Million USD | -3615.04% |
| PureTech Health plc | -167.19 Million USD | 218.462% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 750.246% |
| Elevation Oncology, Inc. | -19.11 Million USD | 1136.013% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 4134.732% |
| Seer, Inc. | -4.24 Million USD | 4771.344% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 924.0% |
| Innoviva, Inc. | 255.56 Million USD | 22.499% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 454.549% |
| ESSA Pharma Inc. | -33.62 Million USD | 689.101% |
| GlycoMimetics, Inc. | -40.98 Million USD | 583.269% |
| GT Biopharma, Inc. | -1.02 Million USD | 19499.119% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 392.205% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -223.334% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 247.723% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 1529.453% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 786.011% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 263015.815% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 741.776% |
| Aptose Biosciences Inc. | -8.19 Million USD | 2516.943% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 6429.941% |
| Soligenix, Inc. | -4.95 Million USD | 4100.023% |
| Century Therapeutics, Inc. | 847 Thousand USD | -23284.298% |
| Kura Oncology, Inc. | -20.11 Million USD | 1084.516% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 583.959% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 2458.478% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -10772.566% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 6295.339% |
| Autolus Therapeutics plc | -186.59 Million USD | 206.145% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 501.722% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 171.816% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -477.988% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | -20.501% |
| GRI Bio, Inc. | -1.79 Million USD | 11140.412% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 2304.876% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 695.559% |
| IGM Biosciences, Inc. | -72.6 Million USD | 372.794% |
| INmune Bio, Inc. | -25.41 Million USD | 879.446% |
| Heron Therapeutics, Inc. | 150.95 Million USD | -31.211% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 490.977% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1318.909% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 6965.514% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -421.018% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 580.915% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -521.186% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 47.595% |
| Verastem, Inc. | -37.27 Million USD | 631.319% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 2283.016% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 481.908% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 1408.655% |
| Histogen Inc. | -7.48 Million USD | 2745.452% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 1016.678% |
| Surrozen, Inc. | -32.66 Million USD | 706.371% |
| Organovo Holdings, Inc. | -1.5 Million USD | 13242.999% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 4811.92% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -944.635% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -7471.292% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -4665.76% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 2463.22% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 555.93% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 1458.763% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 162.523% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 27530.546% |
| Apollomics, Inc. | -27.39 Million USD | 822.997% |
| Amarin Corporation plc | -191.04 Million USD | 203.677% |
| Mesoblast Limited | 55.96 Million USD | -253.921% |
| Turnstone Biologics Corp. | -14.58 Million USD | 1458.098% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 883.113% |
| Synaptogenix, Inc. | -28.66 Million USD | 791.049% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 21260.791% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -306.437% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 23075.006% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 2825.885% |
| Exelixis, Inc. | -73.05 Million USD | 371.136% |
| Better Therapeutics, Inc. | -860 Thousand USD | 23130.814% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 924.824% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 182.058% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -26808.592% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 2762.831% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -15694.657% |
| Gritstone bio, Inc. | 39.49 Million USD | -401.557% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 335.508% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 7624.866% |
| Avid Bioservices, Inc. | 169.72 Million USD | -16.696% |
| Insmed Incorporated | 721.62 Million USD | 72.553% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 2266.655% |
| MediWound Ltd. | -5.32 Million USD | 3821.627% |
| OmniAb, Inc. | 9.2 Million USD | -2052.179% |
| Alector, Inc. | -35.63 Million USD | 655.785% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -130.386% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 4119.176% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -1396.072% |
| Zai Lab Limited | -775 Million USD | 125.557% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 41.841% |
| Aura Biosciences, Inc. | -21.52 Million USD | 1020.163% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 340.137% |
| Immunic, Inc. | -45.34 Million USD | 536.844% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 202.51% |
| Veracyte, Inc. | -203.82 Million USD | 197.175% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 68.97% |
| FibroGen, Inc. | 56.76 Million USD | -248.909% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -2124.2% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 7105.987% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 9666.749% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 95.685% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 6028.315% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 219.342% |
| TG Therapeutics, Inc. | 17.86 Million USD | -1008.862% |
| Galecto, Inc. | -21.21 Million USD | 1033.564% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 932.731% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 87.38% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 909.354% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 1821.257% |
| XBiotech Inc. | -200.02 Million USD | 199.021% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 335.508% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -4274.227% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 661.679% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 356.501% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -3380.32% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 216.225% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 314.416% |
| Vaxxinity, Inc. | 10.13 Million USD | -1854.846% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 73.099% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 1939.462% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 400.299% |
| NexImmune, Inc. | -3.13 Million USD | 6420.599% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 5836.57% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 1410.695% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 830.867% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 2306.593% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 159092.575% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 588.182% |
| Ainos, Inc. | 4.07 Million USD | -4757.001% |
| Pluri Inc. | 22.82 Million USD | -767.603% |
| Prothena Corporation plc | -608.34 Million USD | 132.558% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 266.783% |
| Celularity Inc. | 65.19 Million USD | -203.827% |
| Rallybio Corporation | -24.1 Million USD | 921.778% |
| Cue Biopharma, Inc. | -33.81 Million USD | 685.662% |
| MeiraGTx Holdings plc | -40.3 Million USD | 591.452% |
| Omeros Corporation | 331.17 Million USD | 40.193% |
| Humacyte, Inc. | -22.48 Million USD | 980.837% |
| Immunocore Holdings plc | -358.59 Million USD | 155.234% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 905.961% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 740.966% |
| Blueprint Medicines Corporation | 702.83 Million USD | 71.819% |
| CalciMedica, Inc. | -5.53 Million USD | 3681.646% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 205.231% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 2039.152% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 594.705% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 695.63% |
| Pulmatrix, Inc. | -10.41 Million USD | 2001.363% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 3413.786% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 619.283% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 277.793% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 430.417% |
| Cytokinetics, Incorporated | 642.37 Million USD | 69.167% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 3501.425% |
| Nutriband Inc. | -251.65 Thousand USD | 78804.348% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 680.512% |
| Vor Biopharma Inc. | 4.3 Million USD | -4506.163% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 103.281% |
| Evogene Ltd. | -19.63 Million USD | 1108.786% |
| ProKidney Corp. | -56.23 Million USD | 452.203% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 506.938% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 2244.213% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 85.478% |
| CorMedix Inc. | -43.05 Million USD | 560.055% |
| BioLineRx Ltd. | 7.33 Million USD | -2599.905% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 821.154% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -329.204% |
| Atai Life Sciences N.V. | -28.55 Million USD | 793.553% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -8779.732% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 968.097% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -1016.803% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 363.826% |
| MediciNova, Inc. | -50.78 Million USD | 490.018% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 351.336% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 880584.552% |
| GeoVax Labs, Inc. | -6.45 Million USD | 3169.543% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 199.121% |
| Biomea Fusion, Inc. | -166.57 Million USD | 218.908% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 210.666% |
| Mereo BioPharma Group plc | -51.46 Million USD | 484.824% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 308.832% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 167.424% |
| Absci Corporation | -72.59 Million USD | 372.824% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -4237.823% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 184.485% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 310.236% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 306.973% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 606.91% |
| Allakos Inc. | -24.97 Million USD | 893.053% |
| Imunon, Inc. | -4.21 Million USD | 4800.331% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 1443.542% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 246.281% |
| BioAtla, Inc. | -109.01 Million USD | 281.693% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -26808.592% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 21193.184% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -1555.231% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 1034.137% |
| XOMA Corporation | -29 Million USD | 782.983% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 1296.045% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 2296.817% |
| aTyr Pharma, Inc. | -7.44 Million USD | 2758.948% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 258.915% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 195.149% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 342.195% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 313.517% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 23152.687% |
| Akari Therapeutics, Plc | -3.84 Million USD | 5251.235% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -12104.462% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 85.657% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 16770.244% |
| UroGen Pharma Ltd. | 4.39 Million USD | -4410.704% |
| Sutro Biopharma, Inc. | 113.48 Million USD | -74.536% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -275135.541% |
| Orgenesis Inc. | 21.78 Million USD | -809.222% |
| Entera Bio Ltd. | -10.62 Million USD | 1963.44% |
| GH Research PLC | -78.07 Million USD | 353.679% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 988.662% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 842.957% |
| Xencor, Inc. | 29.64 Million USD | -568.145% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 10155.02% |
| Replimune Group, Inc. | 1.41 Million USD | -13927.266% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 80973.226% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 256.676% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 16770.244% |
| Portage Biotech Inc. | -4.98 Million USD | 4076.41% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 880584.552% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 399.545% |
| OncoCyte Corporation | -6.56 Million USD | 3117.903% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -21970.663% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 4447.685% |
| Purple Biotech Ltd. | -14.13 Million USD | 1500.941% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 933.747% |
| scPharmaceuticals Inc. | -6.54 Million USD | 3126.203% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 1286.575% |
| HilleVax, Inc. | -165.48 Million USD | 219.688% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 7903.98% |
| Tharimmune, Inc. | -10.93 Million USD | 1911.236% |
| Genprex, Inc. | -6.73 Million USD | 3039.684% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 153.704% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 323.903% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 14237.402% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 6071.306% |
| OKYO Pharma Limited | -826.84 Thousand USD | 24054.221% |
| Savara Inc. | 153 Thousand USD | -129354.248% |
| Curis, Inc. | -23.88 Million USD | 929.175% |
| Daré Bioscience, Inc. | -5.15 Million USD | 3940.024% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 25623.446% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 3290.48% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -16614.346% |
| BeiGene, Ltd. | -2.25 Billion USD | 108.791% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -1505.26% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 132.566% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 206.724% |
| Erasca, Inc. | -37.21 Million USD | 632.204% |
| bluebird bio, Inc. | 108.57 Million USD | -82.429% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 15478.995% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 47.705% |
| DBV Technologies S.A. | -126.98 Million USD | 255.974% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 15478.995% |
| Moderna, Inc. | -2.9 Billion USD | 106.813% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 2013.302% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 1922.46% |
| Molecular Templates, Inc. | 707 Thousand USD | -27914.851% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 731.363% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 42.856% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 341.36% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 315.922% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 713.736% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 676.172% |
| MacroGenics, Inc. | -66.98 Million USD | 395.686% |
| RenovoRx, Inc. | -1.17 Million USD | 16985.337% |
| Adicet Bio, Inc. | -138.78 Million USD | 242.711% |
| Prime Medicine, Inc. | -27.94 Million USD | 808.869% |
| Aditxt, Inc. | 18.12 Million USD | -993.021% |
| Adagene Inc. | -87.62 Million USD | 326.031% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 4854.974% |
| Quantum-Si incorporated | -118.55 Million USD | 267.063% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -450.104% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 2749.987% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 508.306% |
| SciSparc Ltd. | -2.06 Million USD | 9691.525% |
| Vericel Corporation | 1.27 Million USD | -15410.18% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1751.684% |
| Minerva Neurosciences, Inc. | 41 Million USD | -383.035% |
| Generation Bio Co. | 31.44 Million USD | -529.817% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 212.945% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 740.51% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | -69.877% |
| Invivyd, Inc. | -198.47 Million USD | 199.793% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 319.414% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 8360.665% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 379.792% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 3002.051% |
| 2seventy bio, Inc. | 181.71 Million USD | -8.998% |
| ADMA Biologics, Inc. | 90.06 Million USD | -119.911% |
| Clene Inc. | 3.34 Million USD | -5830.09% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 2280.683% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 1020.761% |
| GeoVax Labs, Inc. | -6.45 Million USD | 3169.543% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 157.556% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 861.798% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | -11.482% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 4940.81% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -3859.716% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 3902.361% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 252.002% |
| Evaxion Biotech A/S | 5.28 Million USD | -3646.375% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 275.951% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 250.88% |
| Trevena, Inc. | 2.25 Million USD | -8671.701% |
| Surrozen, Inc. | -32.66 Million USD | 706.371% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 484.518% |
| Cingulate Inc. | 3.08 Million USD | -6325.085% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 6843.786% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -2655.879% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 2231.742% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 349.694% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 250.675% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 287.665% |
| Clearmind Medicine Inc. | -3.94 Million USD | 5123.668% |
| Kronos Bio, Inc. | -36.05 Million USD | 649.357% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -2005.059% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -13483.522% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 465.056% |
| Statera Biopharma, Inc. | 14.41 Million USD | -1273.886% |
| ImmunityBio, Inc. | 618.22 Million USD | 67.962% |
| Korro Bio, Inc. | -132.94 Million USD | 248.985% |
| Kineta, Inc. | -4.54 Million USD | 4461.704% |
| BioVie Inc. | -17.73 Million USD | 1216.97% |
| Codexis, Inc. | -43.27 Million USD | 557.732% |
| Celularity Inc. | 65.19 Million USD | -203.827% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 6350.079% |
| Celcuity Inc. | 6.78 Million USD | -2819.802% |
| Virax Biolabs Group Limited | -3.36 Million USD | 5986.131% |
| Cibus, Inc. | -8.07 Million USD | 2551.906% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 4783.495% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -4234.026% |
| IN8bio, Inc. | -16.38 Million USD | 1308.524% |
| Kodiak Sciences Inc. | -103.87 Million USD | 290.676% |
| Annexon, Inc. | -193.75 Million USD | 202.224% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -550080.556% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 1231.865% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 5738.059% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 81.213% |
| Eyenovia, Inc. | 1.25 Million USD | -15635.655% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -636.164% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 6207.462% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 695.738% |
| Arcellx, Inc. | -296.95 Million USD | 166.698% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 1115.406% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 436.416% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 1055.589% |
| Moolec Science SA | 117.61 Thousand USD | -168299.708% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 615.808% |
| Geron Corporation | 14.76 Million USD | -1241.813% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 622.351% |
| Royalty Pharma plc | 5.65 Billion USD | 96.5% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 240.053% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 2933.781% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 3793.273% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 240.74% |
| Humacyte, Inc. | -22.48 Million USD | 980.837% |
| Structure Therapeutics Inc. | -124.33 Million USD | 259.294% |
| 89bio, Inc. | -289.05 Million USD | 168.522% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 884.664% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 11208.525% |
| Genelux Corporation | -6.89 Million USD | 2970.923% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 737.706% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -136.923% |
| Notable Labs, Ltd. | -9.77 Million USD | 2126.033% |
| Liquidia Corporation | -80.17 Million USD | 347.038% |
| Mustang Bio, Inc. | -3.73 Million USD | 5401.526% |
| Immunovant, Inc. | -635.22 Million USD | 131.18% |
| Quantum-Si incorporated | -118.55 Million USD | 267.063% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 1227.676% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 4880.714% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -2367.485% |
| Acasti Pharma Inc. | -23 Million USD | 960.965% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 5982.136% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1318.909% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 243.796% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 6455.648% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 990.901% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 1166.643% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 217.006% |
| PepGen Inc. | -60.67 Million USD | 426.463% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 962.052% |
| United Therapeutics Corporation | -507.7 Million USD | 139.012% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 1135.58% |
| Solid Biosciences Inc. | -47.75 Million USD | 514.796% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 23075.006% |
| Immuneering Corporation | -54.94 Million USD | 460.493% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 4811.92% |
| Silo Pharma, Inc. | -3.52 Million USD | 5719.969% |
| Belite Bio, Inc | -87.27 Million USD | 326.954% |
| XOMA Corporation | -29 Million USD | 782.983% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 380.16% |
| Bionomics Limited | 227 Million USD | 12.75% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 270.332% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 7919.384% |
| uniQure N.V. | -102.95 Million USD | 292.388% |
| Cassava Sciences, Inc. | -121.13 Million USD | 263.506% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 4854.974% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -383.663% |
| Forte Biosciences, Inc. | -11.96 Million USD | 1755.923% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 6501.17% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -186753.774% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 6207.462% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -2124.2% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 2770.779% |
| Altimmune, Inc. | -134.48 Million USD | 247.274% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 7919.384% |
| Compugen Ltd. | -12.9 Million USD | 1634.912% |
| Peak Bio, Inc. | 10.34 Million USD | -1815.493% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 70087.633% |
| Benitec Biopharma Inc. | -50.58 Million USD | 491.572% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 289.83% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -908.221% |
| Zura Bio Limited | -99.8 Million USD | 298.45% |
| PolyPid Ltd. | 6.17 Million USD | -3110.13% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -167.222% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -908.221% |
| Instil Bio, Inc. | 75.35 Million USD | -162.832% |
| argenx SE | -2.02 Billion USD | 109.762% |
| Immunome, Inc. | -97.02 Million USD | 304.13% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 980.485% |
| Verona Pharma plc | -220.44 Million USD | 189.849% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 376.076% |
| Shattuck Labs, Inc. | -121.42 Million USD | 263.118% |
| CervoMed Inc. | -7.79 Million USD | 2641.626% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 206.774% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 4629.271% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 250.345% |
| Moolec Science SA | 117.61 Thousand USD | -168299.708% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 8756.774% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -1145.819% |
| AnaptysBio, Inc. | -18.15 Million USD | 1191.207% |
| Design Therapeutics, Inc. | -18.15 Million USD | 1191.267% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 381.418% |
| NeurAxis, Inc. | 145.7 Thousand USD | -135840.288% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -1663.399% |
| Lumos Pharma, Inc. | -28.49 Million USD | 795.136% |
| Achilles Therapeutics plc | -126.92 Million USD | 256.05% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 376.076% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 30305.267% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 1053.435% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -13483.522% |
| Nutriband Inc. | -251.65 Thousand USD | 78804.348% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 1603.796% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 2762.164% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 41.779% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -734.485% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 144.263% |
| Palisade Bio, Inc. | -12.06 Million USD | 1741.922% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 241.161% |
| Beam Therapeutics Inc. | -262.72 Million USD | 175.39% |
| Neurogene Inc. | -131.95 Million USD | 250.1% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -807.889% |
| AEON Biopharma, Inc. | -4.88 Million USD | 4158.709% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 152.511% |
| Sesen Bio, Inc. | -112.55 Million USD | 275.975% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 298.343% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 8536.221% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 607.521% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 337.824% |
| Athira Pharma, Inc. | -88.99 Million USD | 322.547% |
| Vaccinex, Inc. | -1.28 Million USD | 15477.717% |
| HCW Biologics Inc. | 2.85 Million USD | -6833.408% |
| XOMA Corporation | -29 Million USD | 782.983% |
| Nektar Therapeutics | 210.24 Million USD | 5.791% |
| Arvinas, Inc. | -313.8 Million USD | 163.118% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -12104.462% |
| Merus N.V. | -192.88 Million USD | 202.686% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -230.191% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 2954.785% |
| Rezolute, Inc. | -68.16 Million USD | 390.554% |
| Clene Inc. | 3.34 Million USD | -5830.09% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 1601.972% |
| BeyondSpring Inc. | -13.75 Million USD | 1539.949% |
| Synlogic, Inc. | -6.68 Million USD | 3062.827% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -17366.049% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 2442.578% |
| Peak Bio, Inc. | 10.34 Million USD | -1815.493% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 340.312% |
| Krystal Biotech, Inc. | -350.23 Million USD | 156.552% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | -59.569% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 217.201% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 6373.55% |
| MannKind Corporation | 143.89 Million USD | -37.642% |
| Ikena Oncology, Inc. | -109.15 Million USD | 281.451% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 2716.101% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 698.384% |
| Gossamer Bio, Inc. | 180.35 Million USD | -9.82% |
| CohBar, Inc. | -5.93 Million USD | 3439.639% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 765.809% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -4237.823% |
| Legend Biotech Corporation | -949.39 Million USD | 120.862% |
| Mural Oncology plc | -255.84 Million USD | 177.417% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -514.822% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 4304.629% |
| Disc Medicine, Inc. | -358.28 Million USD | 155.282% |
| Champions Oncology, Inc. | 4.81 Million USD | -4016.064% |
| REGENXBIO Inc. | 54.76 Million USD | -261.644% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 73755.576% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 231.148% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 2297.79% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 345.485% |
| Vaxart, Inc. | -8.24 Million USD | 2503.41% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 494.709% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 255.754% |
| Cellectis S.A. | -43.85 Million USD | 551.636% |
| Longeveron Inc. | -2.9 Million USD | 6911.039% |
| Repare Therapeutics Inc. | -107.85 Million USD | 283.635% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 79.547% |
| Inozyme Pharma, Inc. | 12 Million USD | -1549.992% |
| Revolution Medicines, Inc. | -608.2 Million USD | 132.566% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 16202.846% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 174.709% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 231.98% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 1365.834% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 26865.541% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 102.071% |
| Denali Therapeutics Inc. | -74.86 Million USD | 364.563% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1751.684% |
| Veru Inc. | 4.77 Million USD | -4043.646% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 1861.204% |
| Cingulate Inc. | 3.08 Million USD | -6325.085% |
| Passage Bio, Inc. | 4.58 Million USD | -4219.847% |
| Context Therapeutics Inc. | -14.44 Million USD | 1470.708% |
| Exicure, Inc. | 5.84 Million USD | -3286.305% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 185.975% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 600.543% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -1162.284% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 436.725% |
| Nuvalent, Inc. | -335.38 Million USD | 159.056% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -11320.188% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 365.923% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 2327.953% |
| OmniAb, Inc. | 9.2 Million USD | -2052.179% |
| Anew Medical, Inc. | 1.43 Million USD | -13726.865% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -1109.058% |
| Lipocine Inc. | -4.75 Million USD | 4265.762% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 280.341% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -1200.407% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 490.977% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -695.697% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 3046.957% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 400.887% |
| Ocugen, Inc. | -32.52 Million USD | 709.037% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 331.452% |
| Q32 Bio Inc. | -37.94 Million USD | 621.938% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 31639.013% |
| Alumis Inc. Common Stock | -13.52 Million USD | 1564.003% |
| Equillium, Inc. | -22.39 Million USD | 984.535% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 874.66% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 707.063% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 79992.302% |
| Galera Therapeutics, Inc. | 134.04 Million USD | -47.763% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -6093.402% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -60204.59% |
| Dominari Holdings Inc. | 195 Thousand USD | -101471.795% |
| Edesa Biotech, Inc. | -5.26 Million USD | 3860.554% |
| vTv Therapeutics Inc. | -8.91 Million USD | 2321.207% |
| Bio-Techne Corporation | 267.74 Million USD | 26.025% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 1321.945% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 267.718% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 2457.075% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 1665.607% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 180.804% |
| Nkarta, Inc. | 57.29 Million USD | -245.669% |
| BioCardia, Inc. | 212 Thousand USD | -93326.887% |
| Iterum Therapeutics plc | 13.43 Million USD | -1373.917% |